Understanding Weight Loss Medications

GLP-1 (glucagon-like peptide-1) is a natural hormone released from cells in the small intestine. This hormone:

• Lowers blood glucose by triggering insulin release
• Slows digestion
• Increases feelings of fullness (satiety)

GLP-1 receptor agonist medications mimic these natural actions, reducing appetite and food intake, which results in significant weight loss.

GLP-1 Medications Used for Weight Loss

Bold entries indicate FDA-approved specifically for weight loss. All others are commonly prescribed off-label for weight management.

• Most Effective: Zepbound delivers up to 22.5% weight loss, outperforming other options.
• 2025 Regulatory Changes: FDA has restricted cheaper compounded versions, keeping patient safety at the forefront and directed to FDA-approved brand medications.
• Public Recognition: Media and consumers primarily know these as "Ozempic" “Wegovy” or "weight loss shots".
• Next-Generation Pipeline: Oral Wegovy expected FDA approval Q4 2025; Lilly's oral orforglipron targeting end-2025 submission; Amgen's monthly MariTide in Phase 3 trials readouts expected beginning 2027.

Consumer Behavior Changes:

• Reduced appetite and smaller portion consumption
• Increased focus on nutrient-dense foods
• Need for specialized dietary guidance during treatment

Retailer Opportunities:

• Partner with registered dietitians for GLP-1 patient education
• Develop specialized product sections for weight management
• Create meal solutions for smaller appetites and nutritional needs

Product Supplier Opportunities:

• Focus on nutrient-dense products
• Develop portion-controlled convenience foods
• Address potential nutrient gaps with functional foods

All GLP-1 medications require medical oversight and are prescribed for chronic disease management. The food industry respects the prescriber-patient relationship while positioning grocery retail as a destination for health and wellness support.

The pipeline of next-generation GLP-1 medication options - including oral formulations and extended-dosing regimens - suggests this market disruption is accelerating, not plateauing. Success requires collaboration between healthcare providers, nutrition professionals, and the food industry to support consumers throughout evolving treatment journeys.

The GLP-1 market is moving faster than traditional research cycles can track. While this summary draws from available sources, the most actionable consumer behavior insights are in proprietary research reports.